Navigation Links
MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy

ents to recover more quickly following short surgical and diagnostic procedures and could improve facility and physician practice efficiency."

Bronchoscopy Pivotal Trial Results

A randomized, double-blind, multi-center phase 3 study was conducted to determine the safety and efficacy of Aquavan for the sedation of patients undergoing flexible bronchoscopies. Patients enrolled in this trial had medical histories that included respiratory disorders (88%), vascular disorders (55%), metabolism and nutrition disorders (55%), and infections (52%). Of all patients enrolled in the trial, 62% were found to have a pulmonary or respiratory abnormality at screening including 52% with chronic obstructive pulmonary disease (COPD) and 20% with a lung mass.

A total of 252 patients were randomized and received either a control dose of 2.0 mg/kg Aquavan or a 6.5 mg/kg dose of Aquavan. Following administration of the initial bolus dose of the study drug, the design of this trial allowed a limited number of supplemental doses to be administered to maintain sedation during the procedure.

The primary endpoint of this trial was sedation success, defined as a patient having achieved three consecutive Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scores of less than or equal to 4 after administration of sedative medication and completion of the bronchoscopy procedure without the use of alternative sedative medication and without manual or mechanical ventilation. The secondary endpoint of treatment success was defined as completion of the procedure without the use of alternative sedative medication and without manual or mechanical ventilation. Additional endpoints included measures of patient satisfaction.

Among patients treated with an initial bolus dose of 6.5 mg/kg (n=150) of Aquavan, the sedation success rate was 88.7% compared to 27.5% of patients in the control arm (n=102) (p less than 0.001). The treatment success rate among patients t
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:7/7/2015)... -- The Arentz Law Group is currently investigating cases of birth ... who have taken Zyban while pregnant, and given birth to ... contact the law firm immediately for a free legal ... American Journal of Obstetrics & Gynecology  showed that mothers ... giving birth to a child with " left outflow tract ...
(Date:7/7/2015)... 2015 Biobanks - How to ... ,Are you interested in the future ... technological and commercial predictions from 2015. You stay ahead ... research and development, results, opportunities and revenue forecasts. ... you what,s possible for biobanking and associated technology to ...
(Date:7/7/2015)... 2015   Decision Resources Group finds ... patient management in the U.S. versus the EU5. ... and EU5 nephrologists from approximately 1,870 dialysis patient ... most commonly used renal medications in dialysis patients; ... between the two regions.      Other key ...
Breaking Medicine Technology:Smoking cessation drug linked to birth defects when taken during pregnancy 2Biobanking for Medicine: Technology, Industry and Market 2015-2025 2Biobanking for Medicine: Technology, Industry and Market 2015-2025 3Biobanking for Medicine: Technology, Industry and Market 2015-2025 4Biobanking for Medicine: Technology, Industry and Market 2015-2025 5Biobanking for Medicine: Technology, Industry and Market 2015-2025 6Biobanking for Medicine: Technology, Industry and Market 2015-2025 7Biobanking for Medicine: Technology, Industry and Market 2015-2025 8Biobanking for Medicine: Technology, Industry and Market 2015-2025 9Biobanking for Medicine: Technology, Industry and Market 2015-2025 10Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3
... Approves Label Revisions Recommending New Weight-Based Dosing ... Schering-Plough Corporation,(NYSE: SGP ) today reported ... (FDA),has approved label revisions for PEGINTRON(TM) (peginterferon ... chronic hepatitis C,recommending weight-based dosing of REBETOL ...
... Insulin Should Take Note, Researchers Say, Also: ACC ... ALEXANDRIA, Va., March 27 People who have,diabetes ... who do not,have diabetes, a finding that may have ... a study appearing in the April issue of,Diabetes Care., ...
Cached Medicine Technology:Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C 2Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C 3Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C 4Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C 5Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C 6Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C 7Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C 8Reduced Lung Capacity Accelerates With Diabetes 2Reduced Lung Capacity Accelerates With Diabetes 3
(Date:7/7/2015)... ... July 07, 2015 , ... ... announced the CelestixEdge VE and CelestixFederated VA Series virtual appliances. These virtual ... Series portfolio of products, which have proven to simplify the on-premises deployment of ...
(Date:7/7/2015)... Hong Kong (PRWEB) , ... July 07, 2015 , ... At the end of June ... first steps to ‘go green’ . This initiative, spearheaded by the Renewals Manager, Danielle Cotton, ... Hong Kong office. , On this initiative Cotton explained, “We send anything between 300 ...
(Date:7/7/2015)... ... July 07, 2015 , ... On Saturday, May 16th, 2015, the ... Manistee Golf and Country Club. Best Drug Rehabilitation staff members were delighted to join ... underprivileged children. Kiwanis International, the parent of the Manistee Kiwanis Club, is a global ...
(Date:7/7/2015)... ... July 07, 2015 , ... With a new community program in the ... Angels and announced a new charity campaign to raise funds in support of programs ... Angels, which was created especially to care for the special needs of our soldiers. ...
(Date:7/7/2015)... Horsham, PA (PRWEB) , ... July 07, 2015 ... ... seasoned financial executive Ellen Purdy as the company’s new Chief Financial Officer, effective ... financial and leadership experience in companies ranging from a multi-billion dollar, global chemical ...
Breaking Medicine News(10 mins):Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 2Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 3Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 4Health News:Pacific Prime Hong Kong Renewals Team Starts Push to go Green 2Health News:Best Drug Rehabilitation Team Participates in Kiwanis Club Golf Outing Fundraiser 2Health News:Clear Insurance Group and Nonprofit Soldiers’ Angels Initiate New Charity Campaign in San Antonio, TX to Provide Aid and Comfort for Veterans 2Health News:Clear Insurance Group and Nonprofit Soldiers’ Angels Initiate New Charity Campaign in San Antonio, TX to Provide Aid and Comfort for Veterans 3Health News:Office Practicum Announces new CFO 2
... national study among,467 Americans revealed that a majority ... that he had two conversations with Roger Clemens,about ... use of steroids., (Logo: http://www.newscom.com/cgi-bin/prnh/20071204/NYTU133LOGO ... 18-19 by HCD Research using its,mediacurves.com web site, ...
... Masimo to begin at 2:00 pm PT (5:00 pm ET), ... ), the inventor of Pulse CO-Oximetry and Measure-Through,Motion and Low ... fiscal year 2007 financial results for the period ended,December 29, ... A conference call to review the results will begin ...
... the first animal model of the infection caused by ... epidemics that hit the Indian Ocean (especially the French ... India, and Italy in 2007. Using this mouse ... which tissues and cells are infected by the virus ...
... 2008 -- Persons exposed to radioactive fallout from the ... risk of follicular adenoma or benign tumor of the ... School of Public Health. Results of the study ... diseases, and location of residence do not modify its ...
... Free Samples Now Available for Health-Conscious Consumers Craving Freshly ... Taste for Drinks, Cooking and Seasoning, BALTIMORE, Feb. ... Inc., the makers of True Lemon and True Lime, ... Orange to its,family of products. True Orange provides freshly ...
... tobacco impressions to young audiences annually, and this poses,one ... American Academy of,Pediatrics (AAP). On-screen tobacco recruits 390,000 new ... films take in 58 percent of movie box,office sales ... harm,around the world. The AAP joins many other health ...
Cached Medicine News:Health News:Americans Believe Pettitte had Conversations with Clemens Regarding Both Players' Use of HGH 2Health News:Masimo to Report Fourth Quarter and Fiscal Year 2007 Financial Results on February 26, 2008 2Health News:Researchers create first chikungunya animal model 2Health News:Mailman School PH study finds increase in thyroid diseases risk from exposure at Chernobyl 2Health News:Mailman School PH study finds increase in thyroid diseases risk from exposure at Chernobyl 3Health News:True Orange Joins the True Lemon & True Lime Family 2Health News:True Orange Joins the True Lemon & True Lime Family 3Health News:AAP Calls for an End to 'Toxic' Tobacco Content in Hollywood Movies 2Health News:AAP Calls for an End to 'Toxic' Tobacco Content in Hollywood Movies 3
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
... uncuffed endotracheal tubes are available ... in standard or precut lengths., ... pediatric uncuffed endotracheal tubes are ... with a radiopaque blue line ...
... Line® uncuffed endotracheal tubes are ... styles, in standard or precut ... and pediatric uncuffed endotracheal tubes ... chloride with a radiopaque blue ...
Medicine Products: